Eplerenone improves vascular function and reduces platelet activation in diabetic rats

Journal of Physiology and Pharmacology

Volumn 61, Issue 1, 2010, Pages 45-52

  Schäfer, Andreas ^a   Vogt, C ^a   Fraccarollo, D ^a   Widder, J ^a   Flierl, U ^a   Hildemann, S K ^b   Ertl, G ^a   Bauersachs, J ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Essex Pharma   (Germany)

Author keywords

Aldosterone; Diabetes; Endothelial dysfunction; Nitric oxide; Platelets

Indexed keywords

EPLERENONE; FIBRINOGEN RECEPTOR; GLUCOSE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; NITROUS OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ANTITHROMBOCYTIC AGENT; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FIBRINOGEN SYNTHESIS; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; IMMUNOFLUORESCENCE; LEUKOCYTE COUNT; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; VASCULAR ENDOTHELIUM; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MALE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; SPIRONOLACTONE; VASODILATION;

EID: 77954307695     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Tschoepe D, Menart-Houtermans B. Diabetes mellitus. In: Platelets, Michelson AD (ed). San Diego: Academic Press, 2002; pp.435-445.
2. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001; 27: 436-447.
3. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819-1822.
4. Schafer A, Alp NJ, Cai S, et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol 2004; 24: 1720-1726.
5. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851-860.
7. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25.
8. Madro A, Korolczuk A, Czechowska G, et al. RAS inhibitors decrease apoptosis of acinar cells and increase elimination of pancreatic stellate cells after in the course of experimental chronic pancreatitis induced by dibutyltin dichloride. J Physiol Pharmacol 2008; 59(Suppl 2): 239-249.
9. Han KH, Kang YS, Han SY, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111-120.
10. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
11. Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006;147: 5363-5373.
12. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
13. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292.
14. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-2217.
15. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-328.
16. Bauersachs J, Fraccarollo D. Endothelial NO synthase target of aldosterone. Hypertension 2006; 48: 27-28.
17. Schafer A, Fraccarollo D, Hildemann S, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial function. Cardiovasc Res 2003; 58: 655-662.
18. Schafer A, Fraccarollo D, Hildemann S, et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition: Role of endothelial function and platelet VASP phosphorylation. Thromb Haemost 2003; 89: 1024-1030.
19. Schafer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J. Soluble guanylyl cyclase activation with HMR 1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol 2006; 26: 2813-2818.
20. Schafer A, Fraccarollo D, Eigenthaler M, et al. Rosuvastatin reduces platelet activation in heart failure: role of nitric oxide bioavailability. Arterioscler Thromb Vasc Biol 2005; 25: 1071-1077.
21. 2+-independent activation of the endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1999; 96: 1123-1128.
22. Dikalov S, Griendling KK, Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 2007; 49: 717-727.
23. Fink B, Laude K, McCann L, Doughan A, Harrison DG, Dikalov S. Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am J Physiol Cell Physiol 2004; 287: C895-C902.
24. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
25. Mogensen CE. Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification. Am J Cardiol 1998; 82: 4R-8R.
26. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
27. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin-II suppression. J Endocrinol 1981; 91: 457-465.
28. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736
29. Yoneda T, Takeda Y, Usukura M, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329-1333.
30. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
31. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458.
32. Rugheimer L, Carlsson C, Johnsson C, Hansell P. Renal hyaluronan content during experimental uncontrolled diabetes in rats. J Physiol Pharmacol 2008; 59: 115-128.
33. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-919.
34. Fraccarollo D, Galuppo P, Bauersachs J. Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 287-294.
35. Zayachkivska O, Gzregotsky M, Ferentc M, Yaschenko A, Urbanovych A. Effects of nitrosative stress and reactive oxygen-scavenging systems in esophageal physiopathy under streptozotocin-induced experimental hyperglycemia. J Physiol Pharmacol 2008; 59(Suppl 2): 77-87.
36. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252-1257.
37. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45: 773-779.
38. Kushibiki M, Yamada M, Oikawa K, Tomita H, Osanai T, Okumura K. Aldosterone causes vasoconstriction in coronary arterioles of rats via angiotensin II type-1 receptor: influence of hypertension. Eur J Pharmacol 2007; 572: 182-188.
39. Bauersachs J, Fraccarollo D. More NO-no more ROS: combined selective mineralocorticoid receptor blockade and angiotensin-converting enzyme inhibition for vascular protection. Hypertension 2008; 51: 624-625.
40. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643-650.
41. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-510.
42. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673-678.
43. Jin L, Caldwell RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 2007; 58: 191-206.
44. Schafer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60.
45. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J Physiol Pharmacol 2007; 58: 591-610.
46. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007; 92: 2552-2558.
47. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2216.
48. Sartorio CL, Fraccarollo D, Galuppo P, et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007; 50: 919-925.
49. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to ACE inhibitor in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol 2002; 39: 351-358.
50. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597.
51. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001; 88: 756-762
52. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41(Suppl 2): 26-31
53. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000; 23: 176-180.